Clinical research associate

Mini Series on an Approach to Career and Professional Development in FSP Models, Hosted by Xtalks

Thursday, September 16, 2021 - 1:30pm

Our focus will be on the clinical monitoring (Clinical Research Associate [CRA]) function, but we believe the findings are relevant to any long-term embedded model.

Key Points: 
  • Our focus will be on the clinical monitoring (Clinical Research Associate [CRA]) function, but we believe the findings are relevant to any long-term embedded model.
  • Register for this live mini series to learn how employee retention can be improved in organizations with an FSP model to reduce the risk of staff turnover.
  • Part 1 will take place on Tuesday, October 5, 2021 at 11:30am EDT (4:30pm BST/UK) and will focus on reaping the benefits of a proactive approach to career and professional development in FSP models.
  • For more information, or to register for this event, visit Mini Series on an Approach to Career and Professional Development in FSP Models.

Northstar Engages Boart Longyear for Miller Gold Drill Program and Closes Private Placement

Monday, September 13, 2021 - 9:00pm

Northstar Gold Corp. also announces the Company has closed its second and final tranche of its previously announced $2.5 million non-brokered private placement of units ("Units") for gross proceeds of CDN$104,000.

Key Points: 
  • Northstar Gold Corp. also announces the Company has closed its second and final tranche of its previously announced $2.5 million non-brokered private placement of units ("Units") for gross proceeds of CDN$104,000.
  • Northstar drilled 5,023 metres in 28 holes at Miller in 2020, targeting near-surface high-grade and bulk-tonnage gold-telluride mineralization at Miller.
  • Northstar also commissioned a $350,000 property-wide 3D IP, gravity and magnetic geophysics program on the Miller Gold Property in 2020 to further define gold mineralization controls at depth.
  • Northstar recently completed a 1,990 metre Phase IIA follow up diamond drill program at Miller on April 27th, 2021.

Field Trip Health Ltd. to Pursue Treatment Resistant Depression and Postpartum Depression as Indications for FT-104

Thursday, September 9, 2021 - 12:30pm

TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; NASDAQ: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today the lead indications for FT-104, its novel psychedelic compound in development, will be Treatment Resistant Depression (TRD) and Postpartum Depression (PPD).

Key Points: 
  • TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; NASDAQ: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today the lead indications for FT-104, its novel psychedelic compound in development, will be Treatment Resistant Depression (TRD) and Postpartum Depression (PPD).
  • Through Field Trip Discovery, its drug development division, Field Trip is developing next-generation psychedelic molecules.
  • Major depressive disorder (MDD), treatment-resistant depression (TRD) and postpartum depression (PPD) share similar etiologies and negatively impact functioning.
  • About Field Trip Health Ltd.
    Field Trip is a global leader in the development and delivery of psychedelic therapies.

Northstar Commences Surface Exploration at Miller Gold Property

Tuesday, August 17, 2021 - 1:30pm

Vancouver, British Columbia--(Newsfile Corp. - August 17, 2021) - Northstar Gold Corp. (CSE: NSG) (FSE: 3WV) ("Northstar" or the "Company"), announces that a surface exploration program including prospecting, mechanical stripping, geological mapping and channel sampling of selected areas was initiated at the Miller Gold Property on July 27th, 2021.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - August 17, 2021) - Northstar Gold Corp. (CSE: NSG) (FSE: 3WV) ("Northstar" or the "Company"), announces that a surface exploration program including prospecting, mechanical stripping, geological mapping and channel sampling of selected areas was initiated at the Miller Gold Property on July 27th, 2021.
  • Surface stripping has proven to be highly effective in defining new mineralized zones on the Miller Gold Property as overburden is generally thin.
  • The Company's flagship property is the 100% owned Miller Gold Property, situated 18 km southeast of Kirkland Lake and Kirkland Lake Gold's Macassa SMC gold mine.
  • Northstar's flagship property is the 100% owned Miller Gold Property, situated 18 km southeast of Kirkland Lake and Kirkland Lake Gold's Macassa SMC gold mine.

Northstar Closes First Tranche of Private Placement

Thursday, August 5, 2021 - 1:30pm

Vancouver, British Columbia--(Newsfile Corp. - August 5, 2021) - Northstar Gold Corp. (CSE: NSG) ("Northstar" or the "Company"), announces the Company has closed the first tranche of its previously announced $2.5 million non-brokered private placement of units ("Units"), for gross proceeds of CDN$1,572,220 (the "Offering").

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - August 5, 2021) - Northstar Gold Corp. (CSE: NSG) ("Northstar" or the "Company"), announces the Company has closed the first tranche of its previously announced $2.5 million non-brokered private placement of units ("Units"), for gross proceeds of CDN$1,572,220 (the "Offering").
  • Northstar drilled 5,023 metres in 28 holes at Miller in 2020, targeting near-surface high-grade and bulk-tonnage gold-telluride mineralization at Miller.
  • Northstar recently completed a 1,990 metre Phase IIA follow up diamond drill program at Miller on April 27th, 2021.
  • Northstar is advancing all 3 properties to the NI 43-101 Technical Report stage to maximize geological understanding, increase investor awareness and optimize monetization opportunities.

Marshfield Clinic Research Institute Joins TriNetX to Increase Participation in High-Impact Clinical Trial Opportunities

Monday, July 26, 2021 - 2:00pm

CAMBRIDGE, Mass., July 26, 2021 /PRNewswire/ -- The Marshfield Clinic Research Institute, a division of Marshfield Clinic Inc. and the largest private medical research institute in Wisconsin, has joined the TriNetX network to increase clinical trial opportunities for its largely rural patient population.

Key Points: 
  • CAMBRIDGE, Mass., July 26, 2021 /PRNewswire/ -- The Marshfield Clinic Research Institute, a division of Marshfield Clinic Inc. and the largest private medical research institute in Wisconsin, has joined the TriNetX network to increase clinical trial opportunities for its largely rural patient population.
  • "Marshfield Clinic Research Institute is a leader in clinical trials and research," said Dr. Narayana S. Murali, Executive Director of Marshfield Clinic, Inc. "Being part of the TriNetX network increases our opportunities to participate in high-impact studies and bring the best care to our patients.
  • The Marshfield Clinic Research Institute supports and oversees clinical trials of drugs, devices, and biotechnology conducted at the Marshfield campus and at Marshfield Clinic's regional centers.
  • "Marshfield selected TriNetX as a platform to increase our collaboration with pharmaceutical companies," said Dr. Robert Haws, Director of the Clinical Research Center at the Research Institute.

Specific Diagnostics Announces the Appointment of Scott Wehage as Director of US Clinical Trials

Thursday, April 15, 2021 - 11:00am

b'MOUNTAIN VIEW, Calif., April 15, 2021 /PRNewswire-PRWeb/ --Specific Diagnostics today announced the appointment of Scott Wehage as Director of US Clinical Trials.

Key Points: 
  • b'MOUNTAIN VIEW, Calif., April 15, 2021 /PRNewswire-PRWeb/ --Specific Diagnostics today announced the appointment of Scott Wehage as Director of US Clinical Trials.
  • Previously Mr. Wehage was a Clinical Project Manager for Becton Dickinson\'s Global Clinical Develop Department, where he oversaw clinical trials for device and IVD product development.
  • "\nPrior to joining Specific, Mr. Wehage has worked in clinical research for over 20 years where he managed clinical trials for Becton Dickinson including a large, multisite US trial that ran for more than 4 years.
  • Mr. Wehage has also served as President of the Baltimore Chapter of SoCRA (Society of Clinical Research Associates).

Longboat Clinical Expanding Workforce by 20%

Tuesday, June 23, 2020 - 8:13am

Ken OConnell, Chief Executive Officer at Longboat, commented: We have experienced considerable growth over the last few years and there is a significant demand for the integrated clinical technology approach, quality, and innovation that we provide.

Key Points: 
  • Ken OConnell, Chief Executive Officer at Longboat, commented: We have experienced considerable growth over the last few years and there is a significant demand for the integrated clinical technology approach, quality, and innovation that we provide.
  • The Longboat Platform encompasses a diverse and scalable product suite focused on streamlining clinical trial conduct and reducing the burden on all involved.
  • Longboat is actively supporting patients and caregivers, clinical site staff, study and project teams, and clinical research associates on 160+ clinical trials across 59 countries.
  • Details of the positions available can be found at the dedicated Longboat Careers page, which will be updated as new roles become available https://www.longboat.com/careers .

ConvergeHEALTH by Deloitte Waives Licensing Fees for MyPath for Clinical for COVID and COVID-Impacted Trials

Thursday, June 4, 2020 - 7:30pm

MyPath for Clinical is a cloud-based digital platform designed to enhance the patient experience as well as the success and efficiency of global clinical trials.

Key Points: 
  • MyPath for Clinical is a cloud-based digital platform designed to enhance the patient experience as well as the success and efficiency of global clinical trials.
  • License fees will be waived for organizations that sign up for MyPath for Clinical through August 31, 2020.
  • Fees also will be waived for the duration of the clinical trial in process through its completion.
  • MyPath for Clinical is a modular, patient-centric platform that can help accelerate the execution of digital clinical trials by taking a holistic approach to connect clinical trial participants, investigators and clinical research associates.

Pro-ficiency Partners with ACRP for Best-in-Class Clinical Research Training

Saturday, November 23, 2019 - 12:03am

DURHAM, N.C., Nov. 22, 2019 /PRNewswire/ -- With the goal of providing world-class training and skills advancement tools for research professionals, the Association of Clinical Research Professionals (ACRP) and Pro-ficiency are pleased to announce a strategic partnership.

Key Points: 
  • DURHAM, N.C., Nov. 22, 2019 /PRNewswire/ -- With the goal of providing world-class training and skills advancement tools for research professionals, the Association of Clinical Research Professionals (ACRP) and Pro-ficiency are pleased to announce a strategic partnership.
  • ACRP offers best-in-class training content to the clinical research marketplace.ACRP Certification is the flagship certification in clinical research, earned and supported by more than 33,000 organizations and professionals worldwide.
  • Research shows ACRP Certification results in higher clinical trial enrollment rates, lower protocol deviations, fewer 483 warning letters, improved regulatory compliance, and better inspection performance ( Learn More ).
  • "In clinical research, people are everything," says Jim Kremidas, ACRP Executive Director, "and this new partnership with Pro-ficiency is an exciting opportunity to build on our commitment to the clinical research workforce.